Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
We are on a mission to change the way the world thinks about brain health.
The challenge
The challenge
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate
neurodegenerative diseases.

This gives us the potential to revolutionise how people think about brain health and disease
management.
Our novel technology
assesses brain health based on changes in the cellular structure.
Our solution
Previously inaccessible insights
unlocked by our proprietary technology will support more targeted, efficient drug development.
Supporting more
efficient drug
development and
personalised patient care.
Our science
Latest news
September 2021 - Today, we are delighted to annouce our hospital based research collaboration with Dr Nakajima (Niigata Hospital) and Dr Shigematsu (Miniami Kyoto Hospital). We are very much looking forward to working with our partners to test and validate Cortical Disarray Measurement assessment for handling real world patient MRI images to estimate dementia disease severity. Our press release is also translated in Japanese.
Japan - Research collaboration with Niigata Hospital
NEWS
More
More
6th August 2021

We recently had the honour of hosting Professor Philip Scheltens, MD, PhD as part of the Oxford Brain Diagnostics guest speaker series; he is Professor of Cognitive Neurology and director of the Alzheimer Centre Amsterdam. Professor Scheltens provided valuable insights on the pathway to precision medicine in Alzheimer’s disease, gave his thoughts on the launch of a new class of anti-amyloid drug treatments, and shared his expertise with our team in a Q&A session.
OBD Guest Speaker series - Professor Philips Scheltens
NEWS
More
More
See all news
28th May 2021

We recently had the honour of hosting Renaud La Joie, Assistant Professor in Residence at UCSF, as part of the Oxford Brain Diagnostics guest speaker series. Renaud shared his work showing how Alzheimer’s brain pathology and disease progression are related to various factors such as patient age of onset, clinical syndrome, and APOE. Check out the video above for a clip of the talk, and visit our YouTube channel to access the full length version.
OBD Guest Speaker series - Ass. Professor Renaud La Joie
NEWS
More
More
14th May 2021

Professor Frisoni described how he and his team created a strategic roadmap for developing Alzheimer’s disease biomarkers and discussed how it could be used with Oxford Brain Diagnostics. Click the link (above) to check out the video of the talk using our YouTube channel. Watch out for more videos/discussions in the series to come.
OBD Guest Speaker series -
Professor Giovanni Frisoni
NEWS
More
More
Rethinking
brain health
Our Products
Pharma/Biotech
Clinical
    Measures you can trust
    Get more from your MRI
    Run targeted, more efficient clinical trials
    Efficient use of technology across
    multiple conditions
    Better patient care
    Providing certainty in diagnosis
    Differential diagnosis for Dementia
    Accurately tracking decline
    Proactive brain health

View our Pharma/Biotech products
More Clinical Information
Latest news
See all news
September 2021 - Today, we are delighted to annouce our hospital based research collaboration with Dr Nakajima (Niigata Hospital) and Dr Shigematsu (Miniami Kyoto Hospital). We are very much looking forward to working with our partners to test and validate Cortical Disarray Measurement assessment for handling real world patient MRI images to estimate dementia disease severity. Our press release is also translated in Japanese.
Japan - Research collaboration with Niigata Hospital
NEWS
More
More
6th August 2021

We recently had the honour of hosting Professor Philip Scheltens, MD, PhD as part of the Oxford Brain Diagnostics guest speaker series; he is Professor of Cognitive Neurology and director of the Alzheimer Centre Amsterdam. Professor Scheltens provided valuable insights on the pathway to precision medicine in Alzheimer’s disease, gave his thoughts on the launch of a new class of anti-amyloid drug treatments, and shared his expertise with our team in a Q&A session.
OBD Guest Speaker series -
Professor Philips Scheltens
NEWS
More
More
28th May 2021

We recently had the honour of hosting Renaud La Joie, Assistant Professor in Residence at UCSF, as part of the Oxford Brain Diagnostics guest speaker series. Renaud shared his work showing how Alzheimer’s brain pathology and disease progression are related to various factors such as patient age of onset, clinical syndrome, and APOE. Check out the video above for a clip of the talk, and visit our YouTube channel to access the full length version.
OBD Guest Speaker series -
Ass. Professor Renaud La Joie
NEWS
More
More
14th May 2021

Professor Frisoni described how he and his team created a strategic roadmap for developing Alzheimer’s disease biomarkers and discussed how it could be used with Oxford Brain Diagnostics. Click the link (above) to check out the video of the talk using our YouTube channel. Watch out for more videos/discussions in the series to come.
OBD Guest Speaker series -
Professor Giovanni Frisoni
NEWS
More
More
Rethinking
brain health
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
We are on a mission to change the way the world thinks about brain health.
The challenge
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.

This gives us the potential to revolutionise how people think about brain health and disease
management.
Our novel technology
assesses brain health based on changes in the cellular structure.
Our solution
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Supporting more efficient drug development and
personalised patient care.
Our science
Our science
Pharma/Biotech
    Measures you can trust
    Get more from your MRI
    Run targeted, more efficient clinical trials
    Efficient use of technology across
    multiple conditions
Our Products
Clinical
    Better patient care
    Providing certainty in diagnosis
    Differential diagnosis for Dementia
    Accurately tracking decline
    Proactive brain health

View our Pharma/Biotech products
View our Pharma/Biotech products
More Clinical Information
More Clinical Information
Latest news
See all news
Rethinking
brain health
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
We are on a mission
to change the way the world thinks about brain health.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate
neurodegenerative diseases.

This gives us the potential to revolutionise how people think about brain health and disease management.
Our novel technology assesses brain health based on changes in the cellular structure.
Previously inaccessible insights unlocked by
our proprietary technology will support more targeted, efficient drug development.
Supporting more
efficient drug
development and
personalised patient care.
The challenge
Our solution
Our science
September 2021 - Today, we are delighted to annouce our hospital based research collaboration with Dr Nakajima (Niigata Hospital) and Dr Shigematsu (Miniami Kyoto Hospital). We are very much looking forward to working with our partners to test and validate Cortical Disarray Measurement assessment for handling real world patient MRI images to estimate dementia disease severity. Our press release is also translated in Japanese.
Japan - Research collaboration with Niigata Hospital
NEWS
More
More
6th August 2021

We recently had the honour of hosting Professor Philip Scheltens, MD, PhD as part of the Oxford Brain Diagnostics guest speaker series; he is Professor of Cognitive Neurology and director of the Alzheimer Centre Amsterdam. Professor Scheltens provided valuable insights on the pathway to precision medicine in Alzheimer’s disease, gave his thoughts on the launch of a new class of anti-amyloid drug treatments, and shared his expertise with our team in a Q&A session.
OBD Guest Speaker series -
Professor Philips Scheltens
NEWS
More
More
28th May 2021

We recently had the honour of hosting Renaud La Joie, Assistant Professor in Residence at UCSF, as part of the Oxford Brain Diagnostics guest speaker series. Renaud shared his work showing how Alzheimer’s brain pathology and disease progression are related to various factors such as patient age of onset, clinical syndrome, and APOE. Check out the video above for a clip of the talk, and visit our YouTube channel to access the full length version.
OBD Guest Speaker series -
Ass. Professor Renaud La Joie
NEWS
More
More
14th May 2021

Professor Frisoni described how he and his team created a strategic roadmap for developing Alzheimer’s disease biomarkers and discussed how it could be used with Oxford Brain Diagnostics. Click the link (above) to check out the video of the talk using our YouTube channel. Watch out for more videos/discussions in the series to come.
OBD Guest Speaker series -
Professor Giovanni Frisoni
NEWS
More
More
Our Products
Pharma/Biotech
    Measures you can trust
    Get more from your MRI
    Run targeted, more efficient clinical trials
    Efficient use of technology across
    multiple conditions
Clinical
    Better patient care
    Providing certainty in diagnosis
    Differential diagnosis for Dementia
    Accurately tracking decline
    Proactive brain health

View our Pharma/Biotech products
More Clinical information